Journal of Neural Transmission

, Volume 116, Issue 7, pp 881–884

Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study

  • Giuseppe Meco
  • Paola Stirpe
  • Fabrizio Edito
  • Carlo Purcaro
  • Marcella Valente
  • Silvia Bernardi
  • Nicola Vanacore
Movement Disorders - Short Communication

DOI: 10.1007/s00702-009-0231-z

Cite this article as:
Meco, G., Stirpe, P., Edito, F. et al. J Neural Transm (2009) 116: 881. doi:10.1007/s00702-009-0231-z

Abstract

Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.

Keywords

Parkinson’s diseasel-Dopa-induced dyskinesiasAripiprazole

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Giuseppe Meco
    • 1
    • 3
    • 4
  • Paola Stirpe
    • 1
  • Fabrizio Edito
    • 1
  • Carlo Purcaro
    • 1
  • Marcella Valente
    • 1
    • 3
  • Silvia Bernardi
    • 1
  • Nicola Vanacore
    • 2
  1. 1.Centro Parkinson D.A.I. Neurologia e Psichiatria Policlinico Universitario Umberto I°, “Sapienza”Università di RomaRomeItaly
  2. 2.Istituto Superiore di SanitàRomeItaly
  3. 3.Centro Ricerca Malattie Sociali (CIMS)Università di Roma “Sapienza”RomeItaly
  4. 4.Department of Neurological SciencesSapienza UniversityRomeItaly